ClinicalTrials.gg
Not yet recruitingNCT07140510NaldebainUpdated Aug 24, 2025

Dinalbuphine Sebacate in Postoperative Pain Control After TKA

A Phase 4 interventional study of Dinalbuphine Sebacate and Normal Saline in Osteo Arthritis of the Knee and Total Knee Anthroplasty, sponsored by Thammasat University. Not yet recruiting at 1 site in Thailand. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-08-24.

Sponsored by Thammasat University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
50 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies testing nalbuphine sebacate in Pain, Postoperative — 3 open to participants now, 3 under way, 1 of them phase 3. nalbuphine sebacate · Pain, Postoperative.

Planned enrollment
4th of 11
100 · median 78
Started
2025
the only one that year
Phase 4
6 of 11
1 open now
Registered
11th of 11
by date
Lead sponsor
1 of 11
Thammasat University

Among the 11 studies testing nalbuphine sebacate in Pain, Postoperative, this one is the 4th largest by planned enrollment, is the only one that started in 2025, is one of 6 in phase 4, and was the 11th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

3 of the 11 studies testing nalbuphine sebacate in Pain, Postoperative are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About nalbuphine sebacate

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 50 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing nalbuphine sebacate in Pain, Postoperative, or all of them as a file.
02

Study summary

To evaluate the effectiveness of Dinalbuphine Sebacate for controlling subacute pain after total knee arthroplasty

Read the detailed description

A single dose of intramuscular Dinalbuphine Sebacate can mitigate pain for up to 1 week after TKA

03

Conditions studied

  • Osteo Arthritis of the Knee
  • Total Knee Anthroplasty

Browse trials for

Keywords

  • Dinalbuphine Sebacate
  • Naldebain
  • Subacute pain
  • postoperative pain
  • total knee arthroplasty
04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Osteoarthritic knee patients underwent unilateral primary TKA
  • Age 50-90 years
  • I-III
  • Participants understand and consent to the protocol of the trial

Exclusion criteria

Exclusion Criteria:

  • Morbid obesity (>40)
  • Knee osteoarthritis from inflammatory knee arthritis, trauma, infection
  • Previous knee surgery
  • Cognitive disorder
  • Liver disease
  • Allergy to NSAIDs, opioids, sesame oil, and benzyl benzoate
  • inhibitor and inducer drugs used
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Dinalbuphine Sebacate

    Naldebain 150mg/2mL IM

    Drug: Dinalbuphine Sebacate

  • Placebo comparator
    Placebo

    Normal saline 2 mL IM

    Drug: Normal Saline

Interventions

  • DrugNalbuphine sebacateStudies of Nalbuphine sebacateNalbuphine sebacate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Dinalbuphine Sebacate 150 mg intramuscular injection after spinal anesthesia and adductor canal block in the same side of TKA

  • DrugNormal Saline

    Normal saline 2 mL intramuscular injection after spinal anesthesia and adddutor canal block

06

What researchers measure

Primary outcomes

  1. Visual analog scale for pain (VAS 0-100)

    Visual analog scale for pain at rest and on motion (knee flexion 90 degrees) using 0-100 mm, where a score of 0 represented no pain and 100 indicated the most severe pain

    Time frame: Record every 12 hours after surgery until 2 weeks postoperatively, then once weekly until 12 weeks postopertively

Secondary outcomes

  1. The amount of analgesic drug used

    The amount of IV morphine and oral tramadol (milligram)

    Time frame: During hospitalization and at home until 12 weeks after surgery

  2. Adverse effects

    Incidence of adverse effects including pyrexia, nausea, vomiting, dizziness, injection site pain, and somnolence

    Time frame: The first week after surgery

  3. Length of stay

    Length of stay (day)

    Time frame: During hospitalization (from admission to discharge)

  4. Modified WOMAC score

    Modified Western Ontario and McMaster Universities Osteoarthritis Index score, including total \& subscore. Each item was scored with a Likert scale (0-4). The overall MOWAC was 0-96 (high score = worse symptoms)

    Time frame: At pre-operative, 2 weeks, 6 weeks, and 12 weeks postoperatively

  5. Forgotten Joint Score

    Forgotten Joint Score (Thai version) with 12 questions. Each item was scored on a Likert scale (0-4). The raw score was converted to a 0-100 scale (0 = worst, 100 = best)

    Time frame: At pre-operative, 2 weeks, 6 weeks, and 12 weeks postoperatively

  6. Time up and go (TUG) test

    Time up and go (TUG) test records the time in seconds when the patient starts standing up from the chair, then walks 3 meters at a normal pace, and turns around to sit on the chair.

    Time frame: At pre-operative, 2 weeks, 6 weeks, and 12 weeks postoperatively

  7. Knee range of motion

    Angle of knee flexion and extension in degrees using a long goniometer

    Time frame: At pre-operative, 2 weeks, 6 weeks, and 12 weeks postoperatively

Other outcomes

  1. Rate of closed manipulation

    Closed manipulation under anesthesia due to an unsatisfactory range of motion

    Time frame: At 3 months postoperatively

07

Study locations

1 site
08

References and documents

Publications

  • Yeh CY, Jao SW, Chen JS, Fan CW, Chen HH, Hsieh PS, Wu CC, Lee CC, Kuo YH, Hsieh MC, Huang WS, Chung YC, Liou TY, Chiu HH, Tseng WK, Lee KC, Wang JY. Sebacoyl Dinalbuphine Ester Extended-release Injection for Long-acting Analgesia: A Multicenter, Randomized, Double-Blind, And Placebo-controlled Study in Hemorrhoidectomy Patients. Clin J Pain. 2017 May;33(5):429-434. doi: 10.1097/AJP.0000000000000417. PubMed 27518486 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2025; primary completion for Jun 2026, 8 months later.

Of 535 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's planned 8 months is below that.

Counting every sponsor, half of 545 studies reached it within 16 months; a quarter within 8 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2025
First posted
Aug 24, 2025
StartEst.
Oct 2025
Primary completionEst.
Jun 2026
CompletionEst.
Sep 2026
Last update
Aug 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07140510
Lead sponsor
Thammasat University
Responsible party
Supakit Kanitnate (Principal investigator, Thammasat University) — Principal investigator
First posted
Aug 24, 2025
Start date
Oct 2025 (estimated)
Primary completion
Jun 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Aug 24, 2025

Study contacts

Supakit Kanitnate, M.D.
Contact
naypeng@hotmail.com
+66 899853635

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nalbuphine sebacate

Start the discussion